Vaccine platform

New strategy to prevent viral infections, including coronavirus

  • System rapidly generates vaccine candidates
  • Incorporates multiple peptide-based antigens
  • Increases vaccine efficacy against emerging viral diseases
  • Potential use for COVID-19 (SARS-CoV-2), SARS (SARS-CoV-1), MERS, Ebola, Influenza A and Influenza B

Licensing Manager: Lisa Carlson, PhD or 402-315-0543


New strategy to prevent viral infections, including coronavirus

Researchers at the University of Nebraska Medical Center have developed a modular vaccine system that can be used to generate vaccines against known and emerging viral pathogens. The system can rapidly generate vaccine candidates and allows for the incorporation of multiple peptide-based antigens from a virus of interest or from multiple viruses. Since multiple antigens can be combined in one vaccine, it can help increase the efficacy of vaccines against emerging viral diseases.
Researchers are exploring the use of this new vaccine system for emerging viral diseases such as COVID-19 (SARS-CoV-2), SARS (SARS-CoV-1), MERS and Ebola, as well as for the production of vaccines against well-known viral pathogens such as Influenzas A and B.
To discuss licensing opportunities contact Lisa Carlson, PhD, at or 402-315-0543.